Stengone Carmine N.: insider trades.
Stengone Carmine N. reported 9 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($281K), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 4
- Companies
- 1
- Name as filed
- Stengone Carmine N.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | Director, Officer · CEO and President | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | Contineum Therapeutics, Inc. | S | 2,500 | $16.46 | 17,217 | Form 4 |
| 2026-09-08 | Contineum Therapeutics, Inc. | M | 2,500 | $1.01 | 19,717 | Form 4 |
| 2026-08-03 | Contineum Therapeutics, Inc. | S | 2,500 | $16.01 | 17,217 | Form 4 |
| 2026-08-03 | Contineum Therapeutics, Inc. | M | 2,500 | $1.01 | 19,717 | Form 4 |
| 2026-07-08 | Contineum Therapeutics, Inc. | S | 2,500 | $16 | 17,217 | Form 4 |
| 2026-07-08 | Contineum Therapeutics, Inc. | M | 2,500 | $1.01 | 19,717 | Form 4 |
| 2026-06-30 | Contineum Therapeutics, Inc. | S | 10,000 | $16.01 | 17,217 | Form 4 |
| 2026-06-30 | Contineum Therapeutics, Inc. | M | 7,500 | $1.01 | 24,717 | Form 4 |
| 2026-06-30 | Contineum Therapeutics, Inc. | M | 2,500 | $1.26 | 27,217 | Form 4 |
Questions
What stock did Stengone Carmine N. buy or sell?
Stengone Carmine N. reported 9 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($281K), across 1 company.
Is Stengone Carmine N. the same person as other filers with this name?
This page covers SEC CIK 1861519 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/stengone-carmine-n-1861519.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.